NGS Banner


In this AMP 2023 session, Dr. Klaus Metzeler describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in acute myeloid leukemia (AML), including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.

Data presented by Dr. Metzeler demonstrates the high coverage uniformity of the SureSeq™ Myeloid MRD Panel and the 100% concordance rate he found between OGT’s panel and a locally-developed NGS-based panel. Dr. Metzeler’s results highlight the breadth of clinically relevant variants, including FLT3-ITD mutations, being confidently detected and the potential application of the SureSeq™ Myeloid MRD Panel as a tool for further investigation of MRD in AML samples.


Speaker information

Dr. Klaus H. Metzeler, MDDr. Klaus H. Metzeler, MD

Professor of Translational Hematology, Dept. of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany

  • He obtained his MD from Technical University, Munich, Germany in 2005 and trained as a hemato-oncologist at the University of Munich.
  • He pursued a research fellowship in molecular cancer genetics at the Ohio State University Comprehensive Cancer Center, focusing on prognostic and predictive biomarkers in acute myeloid leukemia (AML).
  • Before moving to Leipzig, was an attending physician, research group leader, and head of the hematological cytomorphology lab at the University of Munich, and established the NGS testing program for hematological malignancies there.
  • His clinical focus is diagnosis and treatment of myeloid malignancies, and his current research interests include translational biomarker studies in myeloid neoplasms including MRD, genetics and clinical relevance of clonal hematopoiesis, and quality of life in AML survivors.

View Dr. Klaus Metzeler's profile on ResearchGate



Recent publications from the speaker

  1. Modeling early treatment response in AML from cell-free tumor DNA
  2. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
  3. Clonal hematopoiesis - From healthy person to leukemia survivors



This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.

SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.

CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter